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Abstract
Background: Methadone is a synthetic opiate mu receptor agonist that is widely used to substitute for illicit
opiates in the management of opiate dependence. It helps prevent opiate users from injecting and sharing
needles which are vehicles for the spread of HIV and other blood borne viruses. This study has the objective of
determining the utility of daily methadone dose to predict retention rates and re-injecting behaviour among
opiate dependents.
Methods: Subjects comprised opiate dependent individuals who met study criteria. They took methadone based
on the Malaysian guidelines and were monitored according to the study protocols. At six months, data was
collected for analyses. The sensitivity and specificity daily methadone doses to predict retention rates and re-
injecting behaviour were evaluated.
Results: Sixty-four patients volunteered to participate but only 35 (54.69%) remained active and 29 (45.31%) were
inactive at 6 months of treatment. Higher doses were significantly correlated with retention rate (p < 0.0001) and
re-injecting behaviour (p < 0.001). Of those retained, 80.0% were on 80 mg or more methadone per day doses
with 20.0% on receiving 40 mg -79 mg.
Conclusions: We concluded that a daily dose of at least 40 mg was required to retain patients in treatment and
to prevent re-injecting behaviour. A dose of at least 80 mg per day was associated with best results.
Background
Opioid dependence and injecting drug use is a serious
world-wide problem. As the global epidemic of heroin
use continues, it adds an increasing burden, driving the
AIDS epidemic in Malaysia and other parts of Asia, with
consequent additional health, economics and social pro-
blems. The primary modes of transmission of HIV
remain to be unprotected penetrative sex and injection-
drug use although other modes also contribute. Direct
blood contact as in the sharing of drug-injection equip-
ment, is a particularly efficient means of transmitting
the virus. In parts of South East Asia and in Malaysia,
the epidemic is driven by injection-drug use. In Malaysia
it is opiate drug use. Malaysia has had to grapple with
drug use problems for as long as it can be remembered.
Despite the avowed objective of becoming “drug-free”
by 2015, the country is still struggling to rid itself of the
menace. In 1986, HIV landed in Malaysia and soon it
got into the drug user population in the country and
injecting opiate use is now feeding the Malaysian epi-
demic [1]. Thus, of the 80,938 cumulative number of
HIV infection in the country at the end of 2007, 58,135
were injecting drug users [2]. The management of opiate
dependence thus presents a great challenge.
Methadone is a μ-opiate receptor agonist developed by
German scientists in the late 1930s. It was approved by
the U.S Food and Drug Administration (FDA) in 1947
as a painkiller, and by 1950 oral methadone also was
used to treat the painful symptoms of persons with-
drawing from heroin [1,3,4]. In 1964, Dole’s team dis-
covered that continous daily doses of oral methadone
were beneficial, allowing otherwise debilitated opioid
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maintenance dose of methadone does not make the
patient feel “high’ or drowsy, so the patient can gener-
ally carry on a normal life. If used properly, methadone
is generally safe and non-toxic with minimal side effect
[5-11].
With the advent of HIV/AIDS in the 80’si ts l o w l y
assumed a central role in the management of opiate
dependence where it has probably revolutionized the
approach with the adoption of maintenance therapy.
Methadone maintenance reduces injection drug use [12]
and is effective in reducing illicit heroin use, HIV risk
behaviors, HIV and other harms associated with illicit
opiate/heroin use [12-14]. Methadone prevents absti-
nence syndrome, reduces narcotic cravings and block
the euphoric effects of illicit opiate use while reducing
the risk for HIV and other BBV transmission. The abil-
ity of methadone to stabilize opiate dependent indivi-
duals provides a platform for addressing the other
biological and social dimensions of opiate dependence.
Many countries have adopted MMT and MMT is now
the most widely used and effective pharmacologic treat-
ment for opiate dependence [15,16]. Apart from bring-
ing health benefits, MMT also reduces illicit opiate use,
improves personal and social functioning and reduces
drug related crimes [1].
Harm reduction came to Malaysia via the Harm Reduc-
tion Working Group at the Malaysia AIDS Council.
Their efforts culminated in the Government approving
harm reduction in 2003 but it was not until 2005-2006
that Methadone Maintenance Therapy (MMT) was intro-
d u c e dt ob ef o l l o w e db yt h eN e e d l ea n dS y r i n g e
Exchange Program (NSEP) and the provision of condoms
[17] apart from the provision of the usual educational
material. As it is with many diseases, MMT is not a cure-
all. It is for this that NSEP is offered. In the private sector
in Malaysia, patients may also obtain alternative therapy
with buprinorphine.
Methadone maintenance therapy (MMT) is generally
considered as corrective therapy, rather than as a “cure”
for opioid addiction, and it had no or only limited effi-
cacy in treating dependence on other substances of
abuse [1]. At appropriate doses it not hinder a patient’s
intellectual capacities or abilities to perform tasks [18]
and it can correct the compulsive use of heroin and
other opiates by addicts [6].
Many factors contribute to the success of MMT but
studies have shown that adequate methadone dosing is
critical [19]. This is because the dose used must be able
to prevent withdrawal, to block craving and perhaps to
also block the effect of additional heroin to discourage
patients from reverting to heroin. For therapeutic suc-
cess, adequate methadone dosing is critical. World-wide,
the dose of methadone varies, with a tendency for a
relatively low daily dose [20]. Malaysia is no exception.
Indeed in private practice in Malaysia, the average dose
is only 10-20 mg methadone per day, and only 5% of
patients receive doses greater 80 mg/day [21]. Even in
the government sector where methadone is provided
free, average daily dose is below 40 mg [22]. The reason
for this is probably not related to the variable pharma-
cology of methadone but rather because many physi-
cians, have at the back of their mind, a belief that “zero
drug is best”. Some physicians also fear the severe
adverse drug response and fatal cardiac problems with
methadone [23,24]. Inadequate doses and premature ter-
mination are the greatest threats to a successful MMT
program in Malaysia. Malaysian doctors tend to use low
doses despite the fact that the traditional dosing with
lower doses are expected to be ineffective [25]. Malay-
sian doctors may outwardly say that they use lower
methadone doses because of their fear for ethnic differ-
ence that would put their patients at higher risks for
toxicity if they were to use doses as high as those
recommended by the Western literature. What they
may not want to admit is the fact that, inwardly, they
have fears with methadone (and all opiates actually!) just
for the simple reason that methadone is an opiate, just
like the dreaded heroin and morphine!. Indeed Malay-
sian doctors are not alone in this. Many doctors every-
w h e r es h a r et h es a m ev i e w .T h u s ,d e s p i t ea m p l e
evidence for the need to maintain patients at a daily
dose of 80 mg to 100 mg, most patients are maintained
on much less, and many are encouraged early termina-
tion. It is probably understa n d a b l et h a tt h el a yp u b l i c
may not understand the scientific basis for MMT and
could be disparaging and become critical of it. It is how-
ever less clear why many physicians and other health
care providers have the same views. Even those directly
involved with MMT programs frequently fail to adhere
to the basic principles of MMT. Most have actually
received clear information on the pharmacologic princi-
ples underlying MMT and their claim that they want to
prescribe as few medications as possible sound hollow,
as they frequently easily prescribe other mood altering
drugs, such as the benzodiazepines that are often pre-
scribed with abandon and can produce psychological
and physiologic dependency. Even if they claim they fear
adverse effects, the adverse, physiologic effects of MMT
are minimal and methadone is probably associated with
the least side effects of any drug in a physician’sp h a r -
macologic armamentarium, when used appropriately.
The real reason is probably more to do with the general
“opiophobias” as it is known that some doctors even
hesitate to use opiates even when indications are clear.
Efforts should therefore be made urgently to reeducate
these doctors. In their hands is the future of the nation.
Their failure to prescribe adequate methadone doses
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consequences.
Our physicians justify the lower methadone doses
used on account of the smaller body sizes of their [26]
and the possibility of reduced drug metabolisms [27].
However, drug metabolism and drug doses do not
depend on the body weight alone. It is more likely to be
related to the expression level and catalytic activity of
the putative drug metabolising enzymes (DME) in the
individual patients [28]. With methadone, metabolism is
complex, mediated by several polymorphic DMEs as
reflected by the large variability observed with metha-
done disposition and half lives [29-31]. DME poly-
morphisms have large geographic and ethnic variations
[32]. With CYP2B6 and CYP3A4, two enzymes that
have been implicated in methadone metabolism, the
ethnic groups in Malaysia show polymorphism with
types and frequencies that differed from each other and
from ethnic groups in other geographic location [33].
Furthermore, the frequencies for mutations at CYP3A4
locus were found to be higher among Malay opiate
dependent individuals compared to non-opiate depen-
dent Malays. CYP3A4 is an enzyme whose activity is
also altered by environmental factors like char-broiled
food and grape fruits [34]. All these would probably
have more impact on methadone dose requirements in
Malaysia than would body weights. However, given the
body of the literature that support the need for adequate
dose, the low doses used can lead to reduced effective-
ness and thus negating the objective of the programmed.
Remaining in treatment for an adequate period of
time is critical for treatment effectiveness. The appropri-
ate duration for an individual depends on their pro-
blems and needs, but research indicates that for most
drug users, the threshold of significant improvement is
reached only after about three months in treatment,
with further gains as treatment is continued. Because
people often leave treatment prematurely, and prema-
ture departure is associated with high rates of relapse to
drug use, programmes need strategies to engage and
keep patients in treatment.
This paper reports retention rates and injecting beha-
v i o u ri np i l o tp a t i e n t sg i v e nd i f f e r e n td o s e so fd a i l y
methadone in MMT programme, two parameters that
are very important for MMT in preventing the spread
of blood borne viruses. This study was performed to
provide a platform for further studies on the pharmaco-
logic optimisation of methadone dose to attain its maxi-
mum benefits.
Methods
Patients
The study was approved by the ethical committee at the
University of Malaya Medical Centre. Patients comprised
opiate dependent individuals who met the inclusion and
exclusion criteria (Table 1) of the national MMT pro-
gram. They gave a written consent prior to the enroll-
ment. They were initiated on a methadone dose based on
the guidelines of the Malaysian Ministry of Health. The
administration of methadone was directly observed by
the prescribing physician. Patients were monitored
according our study protocols and the guidelines to
monitor opiate usage and injecting behavior. At six
months, data was collected for analyses.
Statistical Methods
At the end of six months, patients’ data were collated.
Patients were divided into 3 groups according to the
daily dose level that they received, “low dose” (0-39 mg),
“intermediate dose” (40-79 mg) and “high dose” (80 mg
or more) [19]. Summary statistics were calculated.
Differences between groups were tested for signifi-
cance using the chi-square test and p value of less than
0.05 was taken as signifying statistical significance.
Additionally, sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) were
also calculated using the following formula and defini-
tion. This was done with the view of using daily dose
groups to predict successful methadone therapy, i.e.,
knowing the daily dose, how sure we are that MMT will
give good outcomes in the affected patients. For the pur-
pose of data analysis “inadequate dose” methadone group
and “adequate dose” methadone groups were classified.
“inadequate dose” group is defined as daily methadone
doses of less 80 mg and “adequate dose” group is defined
as daily methadone dose of more than 80 mg.
Sensitivity
Number of true positive
Number of true positive
=
+ +
×
Number of false negative
100%
Specificity
Number of true negative
Number of true negative
=
+ +
×
Number of false positive
100%
PPV
Number of true positive
Number of true positive Number 
=
+ o of false positive
×100%
NPV
Number of true negative
Number of true negative Number 
=
+ o of false negative
×100%
For retention rate, the true positive is defined as those
patients on “adequate dose” who remain active on treat-
ment, true negative is defined as those patients on
“inadequate dose” and are defaulter to treatment, false
positive is defined as those patients on “inadequate
dose” but remain active and false negative is defined as
those patients on adequate dose but defaulted treatment.
For re-injecting behavior, the true positive is defined as
those patients on “adequate dose” and not re-injecting,
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dose” and has re-injecting behavior, false positive is
defined as those patients on “inadequate dose” but show
no re-injecting behavior and false negative is defined as
those patients on “adequate dose” but exhibit re-injecting
behavior. All statistics were performed using SPSS (SPSS
Inc, Ill, v 13) on an IBM-compatible computer.
Results
Sixty-four patients were enrolled for this pilot study. All
were Malay males. The youngest was 20 years old and
the oldest 56. All have had a long history of illicit drug
use exceeding 2 years. The youngest age at which they
first took illicit drugs was 12 years. Their doses were
titrated appropriately as tolerated and the final dose
averaged 57.2 mg (SD ± 22.7) with a range from 20 to
160 mg per day and a median of 50 mg. Table 2 details
the characteristics of the study patients.
Overall retention rate at 6-month was 54.69% with 29
patients lost to follow up. Of the “retained” patients,
80% were receiving doses of 80 mg or more per day.
None was found in the 0 - 39 mg per day dose group.
Retention rate for the 40 - 79 mg per day dose group
was 20%. As shown in Table 3 and 4, the differences
between the dose groups in terms of retention rates
reached and re-injecting behavior statistical significance
(p = 0.001).
In terms of using methadone daily doses greater than
80 mg as a predictor of a successful outcome for MMT
(as measured by retention rates and re-injection beha-
vior), we found that the positive predictive value of
doses greater than 80 mg a day to predict retention was
80% and its negative predictive value was 93%. This
means that, in terms of predicting retention, a daily
dose exceeding 80 mg will have a probability of 0.8 in
accurately predicting that the patient will be retained in
treatment. In terms of predicting failure to retain, it has
a probability of 0.93 in making an accurate prediction.
A similar probability was also calculated with regards
re-injecting behavior but in terms of predicting non-
re-injecting, the probability of accurate prediction is
only 0.73.
Discussion
Over time, many important discoveries have revolutio-
nized the practice of medicine. The discovery of penicil-
lin and other antibiotics for instance, have changed the
ways infectious diseases are treated and the discovery of
X-rays has introduced new ways for diagnostics. Metha-
done could have occupied a similar position but for the
stigma and discrimination that drug use disorder and
opiate use suffer from.
The 21
st century saw Malaysia leading the pact of
countries with a most rapidly rising HIV epidemic. After
tireless efforts by individuals and organizations, MMT
was finally instituted in the country. The program is
now implemented at public and private health facilities
and other facilities involved with drug use communities.
The primary goal is to blunt the rapid rise in HIV infec-
tions although the public mainly see it as a treatment
for drug addiction. This paper reports a finding from a
pilot project on MMT in a small cohort of injecting
drug users in SAHABAT and Klinik Dr Khafiz. It is
intended to provide a basis for a more comprehensive
research to understand factors that can contribute to
successes with MMT as, among heroin drug users,
MMT has demonstrated effectiveness in reducing HIV
Table 1 The criteria of enrollment as recommended by Ministry of Health, Malaysia
Criteria Inclusion Exclusion
1. Opiate dependence by DSM IV criteria 1. Defaulter treatment for more than 3 days.
2. Age 18 years and above 2. Behavior judged by treating physician to be destructive to MMT clinic.
3. Willing to comply with the daily Direct Observation
Therapy Supervision (DOTS) and dosing.
Table 2 Demography of study patients
Details N %
Gender:
-Male 64 100
-Female 0
Age:
-Youngest 20
-Eldest 56
-Mean: 33
Age at 1
st time illicit drug use
-As young as 12 year-old
-As old as 32 year-old
-Mean 20 year-old
Duration of Opiate Addiction:
-Minimum 2 years
-Maximum 38 years
-Mean 13 years
HIV infection status
-Positive 23 36
-Negative 37 58
-Unknown 4 8
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grams in Malaysia are implemented in government hos-
pitals as well as in private practice.
SAHABAT is a non-governmental organisation work-
ing for and with drug use communities in Kelantan.
MMT was introduced in SAHABAT in 2008. SAHA-
BAT is the first centre in Malaysia to have both the
MMT program and NSEP running under one roof.
SAHABAT also boasts as the only NGO-run centre that
was allowed to prescribe methadone. The other centre
included in this study was Klinik Dr Khafiz, a general
practice clinic near Kuala Lumpur. It was included to
provide an insight of MMT practice in the community.
In this study, all the patients enrolled were males in
the productive age group. This underscores the impor-
tance of proper management of opiate addiction because
of its potential influence onp o p u l a t i o ng r o w t h ,d e m o -
graphy as well as productivity of the nation as young
males play a significant role in providing Malaysia’s
work force. Of note was a high prevalence of HIV posi-
tivity. In most countries that practice harm reduction
among injecting drug users, the incidence of HIV posi-
tivity is generally 1-2% [35]. The high prevalence seen in
our Malaysian cohort suggests the need for urgent effec-
tive measure to control. This is now done in Malaysia
with MMT and NSEP.
Drug use disorder is a chronic relapsing disease. Our
study revealed that no age group is spared. Our young-
est patient was 20 years-old. They began their drug
habit as early as when they were 12 years. The oldest
patient was 56 years and the oldest age a patient started
with the habit was 32 years. The duration of illness
among our patients ranged from two years to 38 years
and averaged 13 years. These have implications. For
one, preventive measures for drug use disorder must
begin early and should be continued through all ages.
Patients afflicted with the disease should also have long
follow ups as they evidently continue with their habits
right through their golden years. The longer they con-
tinue on the habit, the greater is the chance for them to
contract diseases like HIV, if they have not yet been
infected. Being young and otherwise healthy, young
addicts may find themselves constrained in various
activities and this may lead them to many other
unhealthy practices.
Drug users do not live in isolation. Apart from trans-
mission through the sharing of injection equipments,
having the HIV reservoir, drug users can also transmit
the disease to their sexual partners, through penetrative
sex. Thus, what started in Malaysia as a concentrated epi-
demic among drug users is now showing evidence for a
more generalized epidemic through sexual transmission.
Table 3 Retention status of patients in MMT programme at 6 months follow-up
Retention
Status at 6
months
Group of Methadone Doses Total p-value Sensitivity Specificity Positive predictive value
(PPV)
Negative predictive value
(NPV)
80 mg &
below
80 mg &
above
Active n 7 28 35
% 20 80 100
Defaulter n 27 2 29 0.001 80.00% 93.10% 93.30% 79.40%
% 93 7 100
Total n 34 30 64
% 53 47 100
Table 4 Re-injecting behaviour of patients in MMT programme at 6 months follow-up
Re-
injecting
behaviour
at 6
month
Group of Methadone Doses Total p-value Sensitivity Specificity Positive predictive value
(PPV)
Negative predictive value
(NPV)
80 mg &
below
80 mg &
more
Yes n 24 9 33 0.001 71.00% 73.00% 71.00% 73.00%
% 73 27 100
No n 9 22 31
% 29 71 100
Total n 33 31 64
% 52 48 100
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were females. Now it stands at about 20% and this clearly
demonstrates the generalization of the HIV epidemic in
Malaysia. Most of the afflicted females are also wives and
spouses of drug users who are themselves HIV positive
and not sex workers as many would have expected.
There is however evidence for a growing epidemic
among sex workers and this again has the potential to
generalize into the community.
A most important characteristic of a good MMT pro-
gram is high retention rate [36]. Our overall retention
rate at 6 months was low. Coupled with the relatively
small percentage of opiate-dependent individuals having
access to MMT in Malaysia, this may threaten the suc-
cess of MMT as a tool to reduce HIV spread in Malaysia.
T h el o wr e t e n t i o nr a t ew es a ww a sp r o b a b l yd u et ot h e
low daily maintenance dose of methadone our patients
got. Our daily doses averaged 57 mg. Its median was
lower at 50 mg. Our results revealed that best retention
rates were obtained among patients treated with 80 mg
or more methadone per day. In parallel, our patients trea-
ted with 80 mg or more methadone per day showed the
least tendency for re-injecting. It is therefore interesting
to note that, despite claims by many physicians that rela-
tively lower doses of methadone would be sufficient for
our Malaysian patients, our results showed otherwise.
Our findings were also in parallel with studies that
showed a sufficiently high dose was required for
improved outcomes [37]. High doses suppress illicit her-
oin use and improve retention and outcomes [38,39].
Dole’s original research discovered that 80 to 120 milli-
grams of methadone per day, on average, was an effective
dose. Dozens of studies since then have demonstrated
that dosing in that range resulted in superior treatment
outcomes, such as better retention of patients in treat-
ment and less illicit drug use [9,11,39]. Patients main-
tained on inadequately low doses are much more likely
to use illicit opioids and respond poorly to therapy [18].
A study by Strain et al [40] also concluded that patients
receiving 80 mg or more methadone per day had signifi-
cantly greater decreases in illicit opiod use. Another
study concluded that a sufficiently high dose of substitu-
tion therapy was required for improved outcome [37]
and many other independent studies also showed that
high doses of methadone were significantly more effec-
tive in suppressing illicit heroin use and in retaining
patients in the treatment [38,41,42].
Inadequate doses and premature termination will
probably be the greatest threats to a successful MMT
program in Malaysia. Malaysian doctors tend to use low
doses despite the fact that the traditional dosing with
lower doses are expected to be ineffective [43]. Many
also actively encourage their patients to terminate MMT
early. They may outwardly say that they use lower
methadone doses because of fear for ethnic difference
that would put patients at risks for toxicity. They will
not admit their fears with methadone (and all opiates
actually!) just for the simple reason that methadone is
an opiate, just like heroin and morphine!. Malaysian
doctors are not alone in this. Despite evidence for the
need for a daily dose of 80 mg to 100 mg, most patients
are maintained on much less. It is probably understand-
able that the lay public may not understand the scienti-
fic basis for MMT and could be disparaging and
become critical of it. It is however less clear why many
physicians and other health care providers have the
same views. Most have actually received clear informa-
tion on the principles underlying MMT. They may also
claim that they want to prescribe as few medications as
possible but this sounds hollow. Many frequently easily
prescribe other mood altering drugs, such as the benzo-
diazepines that can also produce psychologic and phy-
siologic dependency. Even if they claim they fear
adverse effects, the adverse, physiologic effects of MMT
are minimal and methadone is probably associated with
the least side effects of any drug in a physician’sp h a r -
macologic armamentarium, when used appropriately.
Illicit use of benzodiazepines, even among MMT
patients, are now threatening to derail the MMT pro-
gram as many continue to inject benzodiazepines
although they may have discontinued injecting opiates.
There is probably a general “opiophobias”.I ti sk n o w n
that some doctors even hesitate to use opiates even
when indications are clear. Efforts should therefore be
made urgently to reeducate these doctors. In their
hands is the future of the nation. Their failure to pre-
scribe adequate methadone doses will lead to therapeu-
tic failure for MMT and this has dire consequences.
Our physicians justify the lower methadone doses used
on account of the smaller body sizes of their [26] and the
possibility of reduced drug metabolisms [27]. However,
drug metabolism and drug doses do not depend on the
body weight alone. It is more likely to be related to the
expression level and catalytic activity of the putative drug
metabolising enzymes (DME) in the individual patients
[28]. With methadone, metabolism is complex, mediated
by several polymorphic DMEs as reflected by the large
variability observed with methadone disposition and half
lives [29-31]. DME polymorphisms have large geographic
and ethnic variations [32]. With CYP2B6 and CYP3A4,
two enzymes that have been implicated in methadone
metabolism, the ethnic groups in Malaysia show poly-
morphism with types and frequencies that differed from
each other and from ethnic groups in other geographic
location [33]. Furthermore, the frequencies for mutations
at CYP3A4 locus were found to be higher among Malay
opiate dependent individuals compared to non-opiate
dependent Malays. CYP3A4 is an enzyme whose activity
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food and grape fruits [34]. All these would probably have
more impact on methadone dose requirements in Malay-
sia than would body weights.
Nevertheless, as with many drugs, the dosing of
methadone must be individualised [19]. Too low a dose
will lead to relapse and failure whereas too high a dose
will lead to toxicity such as prolongation of QT interval
and subsequent fatal polymorphic ventricular fibrillation
[20]. For some reasons such as, pharmacologic variabil-
ity at the enzyme and receptor levels, high tolerance to
opioids, physical condition, mental status, concurrent
medications, or prior use of high-purity heroin, however,
some patients require much higher daily methadone
doses for treatment success, sometimes exceeding 200
mg/day or more [10,11,44].
Conclusions
We conclude that MMT in Malaysia is faced with the chal-
lenge of retaining patients in the program as a relatively
low retention rate was found in our cohort of patients. For
this, an adequate daily dose of methadone (typically at least
80 mg per day) was an important modifiable determinant
to achieve higher retention rates and minimizing re-inject-
ing behaviour among these opiate dependent individuals
on MMT. Knowledge of daily methadone doses is a useful
predictor of a successful MMT.
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